



Oncology Off-Label Indications and Recommendations

(Note: This listing is not inclusive of all off-label oncology indications; a complete list is forthcoming)

Drug (Type of Request)	Review Date	Recommendation	Strength Of Recommendation	Level of Evidence Rating
Abemaciclib (Internal Review)	11/14/2017	For the use of abemaciclib for the first-line treatment of HR-positive, HER2-negative advanced breast cancer, in combination with an aromatase inhibitor	Equivocal/Weak For	Low
Abiraterone (External Request - Janssen Pharmaceuticals, Inc.)	12/26/2017	For the use of abiraterone for the treatment of metastatic, hormone-sensitive prostate cancer, in combination with prednisone and androgen-deprivation therapy	Strong For	Moderate
Ado-trastuzumab emtansine (Internal Review)	12/21/2016	For the use of ado-trastuzumab emtansine for the first-line treatment of HER2-positive advanced breast cancer	Equivocal/Weak For	Moderate
Aldesleukin (Internal Review)	11/4/2011	Against the use of aldesleukin, IL-2 for the treatment of relapsed or refractory acute myelogenous leukemia (AML)	Equivocal/Weak Against	Low
Aldesleukin (Internal Review)	11/14/2011	Against the use of aldesleukin, IL-2 for consolidation treatment in patients with acute myelogenous leukemia (AML) following chemotherapy or autologous bone marrow transplantation	Strong Against	Moderate
Aldesleukin (Internal Review)	11/14/2011	For the use of aldesleukin, IL-2 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sezary syndrome	Equivocal/Weak For	Low
Aldesleukin (Internal Review)	12/10/2014	For the use of aldesleukin for the treatment of steroid-refractory chronic graft-versus-host disease	Equivocal/Weak For	Very Low
Alemtuzumab (Internal Review)	10/10/11	For the use of alemtuzumab for the treatment of relapsed or refractory CLL in combination with rituximab	Equivocal/Weak For	Low
Alemtuzumab (Internal Review)	12/23/13	For the use of alemtuzumab for the treatment of relapsed or refractory CLL in combination with fludarabine	Equivocal/Weak For	Moderate
Alemtuzumab (Internal Review)	10/11/11	For the use of alemtuzumab for the treatment of T-cell prolymphocytic leukemia (PLL)	Equivocal/Weak For	Low
Alemtuzumab (Internal Review)	10/11/11	For the use of alemtuzumab in combination with fludarabine and melphalan for graft-versus-host disease prophylaxis in nonmyeloablative allogeneic hematopoietic stem cell transplantation (SCT) in patients with hematologic malignancies	Equivocal/Weak For	Low
Alemtuzumab (Internal Review)	10/14/11	For the use of alemtuzumab for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome	Strong For	Low
Anastrozole (Internal Review)	10/3/11	For the use of anastrozole for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, after 2 to 3 years of tamoxifen therapy to complete a total of 5 consecutive years of adjuvant hormonal therapy	Strong For	High
Arsenic Trioxide (Internal Review)	10/12/11	For the use of arsenic trioxide as consolidation treatment in newly diagnosed acute promyelocytic leukemia following remission induction with all-trans retinoic acid plus anthracycline-based chemotherapy	Strong For	High

Atezolizumab	10/10/16	For the use of atezolizumab for the treatment of locally advanced or metastatic non-small cell lung cancer, with progression on or after platinum-based chemotherapy	Weak For	Moderate
Atezolizumab	8/9/18	For the use of atezolizumab for the first-line treatment of advanced or metastatic renal cell carcinoma, in combination with bevacizumab	Weak For	Low
Axitinib	10/21/16	For the use of axitinib in the first-line treatment of advanced or metastatic renal cell carcinoma	Weak For	Very Low
Azacitidine (Internal Review)	10/3/11	For the use of azacitidine in combination with mitoxantrone for the treatment of patients with chronic myelogenous leukemia in accelerated phase or blast crisis	Equivocal/Weak For	Low
Azacitidine (Internal Review)	4/3/19	For the use of azacitidine for the treatment of newly diagnosed acute myelogenous leukemia in elderly patients who are ineligible for a hematopoietic stem-cell transplant	Equivocal/Weak For	Moderate
Bendamustine (Internal Review)	6/21/17	For the use of bendamustine for the treatment of relapsed or refractory peripheral T-cell lymphoma	Equivocal/Weak For	Low
Bendamustine (Internal Review)	10/3/13	For the use of bendamustine in combination with rituximab for the treatment of previously untreated indolent NHL (including follicular lymphoma)	Strong For	Moderate
Bendamustine (Internal Review)	10/5/11	For the use of bendamustine in combination with rituximab for the treatment of previously treated mantle cell lymphoma (MCL)	Strong For	Low
Bendamustine (Internal Review)	10/3/13	For the use of bendamustine in combination with rituximab for the treatment of previously untreated mantle cell lymphoma (MCL)	Strong For	Moderate
Bendamustine (Internal Review)	12/11/14	Against the use of bendamustine for the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in pediatric patients	Equivocal/Weak Against	Very Low
Bevacizumab (External Request - Genentech)	3/5/12	For the use of bevacizumab in combination with trastuzumab and docetaxel for the first-line treatment of HER2-positive locally recurrent or metastatic breast cancer	Equivocal/Weak For	Low
Bevacizumab (Internal Review)	10/24/11	Against the use of bevacizumab for the treatment of advanced pancreatic cancer in combination with gemcitabine with or without erlotinib	Equivocal/Weak Against	Moderate
Bevacizumab (Internal Review)	12/14/11	For the use of bevacizumab in combination with paclitaxel for patients who have not previously received chemotherapy for metastatic HER2-negative breast cancer	Equivocal/Weak For	High
Bevacizumab (Internal Review)	1/13/12	For the use of bevacizumab in combination with paclitaxel for patients who have not previously received chemotherapy for metastatic HER2-negative breast cancer	Equivocal/Weak For	Low
Bevacizumab (Internal Review)	3/5/12	For the use of bevacizumab in combination with capecitabine for the treatment of relapsed or refractory metastatic breast cancer	Equivocal/Weak For	Moderate
Bevacizumab (Internal Review)	5/1/12	For the use of bevacizumab for the treatment of recurrent, platinum-sensitive ovarian cancer in combination with gemcitabine and carboplatin	Equivocal/Weak For	Moderate
Bevacizumab (Internal Review)	5/1/12	For the use of bevacizumab in combination with carboplatin and paclitaxel for the adjuvant treatment of newly diagnosed ovarian cancer	Equivocal/Weak For	Moderate
Bevacizumab (Internal Review)	5/1/12	For the use of bevacizumab as a single agent for the treatment of recurrent or relapsed ovarian cancer	Equivocal/Weak For	Low
Bevacizumab (Internal Review)	11/15/13	Against the use of bevacizumab in combination with temozolomide and radiation therapy for the first-line treatment of glioblastoma multiforme	Equivocal/Weak Against	Moderate

Bevacizumab (External Request - Genentech)	7/27/16	For the use of bevacizumab in combination with cisplatin and pemetrexed for the treatment of previously untreated advanced, unresectable malignant pleural mesothelioma	Strong For	Low
Bexarotene (Internal Review)	12/10/14	Against the use of bexarotene for the treatment of metastatic breast cancer	Equivocal/Weak Against	Low
Bexarotene (Internal Review)	10/10/11	Against the use of bexarotene for the first-line treatment of advanced non-small-cell lung cancer, as part of combination chemotherapy	Strong Against	High
Bexarotene (Internal Review)	10/10/11	Against the use of bexarotene for the treatment of AIDS-related Kaposi sarcoma	Equivocal/Weak Against	Very Low
Bleomycin (Internal Review)	9/13/12	For the use of bleomycin in combination with doxorubicin plus vincristine for the treatment of AIDS-related Kaposi's sarcoma	Strong For	High
Bleomycin (Internal Review)	12/4/12	For the use of bleomycin for the treatment of malignant ascites	Equivocal/Weak For	Very Low
Bortezomib (Internal Review)	10/3/11	For the use of bortezomib for the treatment of relapsed or refractory low-grade B-cell non-Hodgkin lymphoma	Equivocal/Weak For	Low
Bortezomib (Internal Review)	10/15/13	For the use of bortezomib in combination with thalidomide and dexamethasone as induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma	Strong For	Low
Bortezomib (Internal Review)	8/31/12	For the use of bortezomib in combination with dexamethasone as induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma	Strong For	Low
Bortezomib (Internal Review)	7/7/15	For the use of bortezomib and vorinostat for the treatment of relapsed/refractory multiple myeloma	Weak For	Moderate
Bortezomib (Internal Review)	3/3/17	For the use of bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma	Strong For	Moderate
Brentuximab (Internal Review)	3/12/18	For the use of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for the treatment of previously untreated advanced classical Hodgkin lymphoma	Weak For	Moderate
Brentuximab (Internal Review)	6/30/17	For the use of brentuximab for the treatment of previously treated CD30-positive cutaneous T-cell lymphoma, specifically mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma	Weak For	Low
Brentuximab (External Review)	7/31/15	For the use of brentuximab as consolidation therapy following an autologous stem cell transplant for relapsed or primary refractory Hodgkin lymphoma in patients at high risk for progression	Weak For	Low
Busulfan (Internal Review)	6/16/17	For the use of busulfan and melphalan as stem cell transplant preparation prior to autologous hematopoietic stem-cell transplantation in patients with high-risk neuroblastoma (Pediatrics and Adults less than 21 years), in combination with melphalan	Strong For	Low
Busulfan (Internal Review)	10/14/11	For the use of busulfan for stem cell transplant preparation prior to allogeneic transplantation for acute myelogenous leukemia, in combination with cyclophosphamide	Equivocal/Weak For	Low
Busulfan (Internal Review)	10/14/11	For the use of busulfan for stem-cell transplant preparation prior to autologous transplantation for non-Hodgkin lymphoma, in combination with cyclophosphamide or cyclophosphamide plus etoposide	Equivocal/Weak For	Low
Busulfan (Internal Review)	6/20/19	Intravenous busulfan and melphalan as stem cell transplant preparation prior to autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (Adults 70 years or younger)	Equivocal/Weak For	Low

Cabozantinib	12/5/16	For the use of cabozantinib for the first-line treatment of metastatic renal cell carcinoma in poor or intermediate risk patients	Equivocal/Weak For	Low
Cabozantinib	8/8/18	For the use of cabozantinib for the treatment of advanced hepatocellular cancer, after progression on sorafenib	Equivocal/Weak For	Moderate
Capecitabine (External Request - Genentech)	10/3/11	For the use of capecitabine in combination with oxaliplatin for the adjuvant treatment of stage II-IIIB gastric cancer	Equivocal/Weak For	Moderate
Capecitabine (Internal Review)	10/3/11	For the use of capecitabine in combination with cisplatin for the treatment of advanced gastric cancer	Strong For	Moderate
Capecitabine (Internal Review)	10/3/11	For the use of capecitabine in combination with epirubicin and cisplatin or oxaliplatin for the treatment of advanced gastric cancer	Strong For	Moderate
Capecitabine (Internal Review)	10/19/11	For the use of capecitabine in combination with oxaliplatin for the treatment of metastatic colorectal cancer	Strong For	Moderate
Capecitabine (Internal Review)	10/19/11	For the use of capecitabine in combination with oxaliplatin and bevacizumab for the treatment of metastatic colorectal cancer	Strong For	Moderate
Capecitabine (Internal Review)	10/20/11	For the use of capecitabine for the treatment of inoperable, recurrent, platinum- and taxane-resistant ovarian cancer	Equivocal/Weak For	Low
Capecitabine (Internal Review)	10/25/11	For the use of capecitabine in combination with other chemotherapy agents for the treatment of unresectable advanced or metastatic biliary tract cancer	Equivocal/Weak For	Low
Carboplatin (Internal Review)	8/20/12	For the use of carboplatin in combination with paclitaxel for the first-line treatment of metastatic breast cancer	Equivocal/Weak For	Moderate
Carboplatin (Internal Review)	10/19/12	For the use of carboplatin in combination with etoposide for the treatment of extensive disease small cell lung cancer	Strong For	Moderate
Carboplatin (Internal Review)	10/19/12	For the use of carboplatin in combination with etoposide and thoracic irradiation for the treatment of limited disease small cell lung cancer	Strong For	Low
Carboplatin (Internal Review)	10/19/12	For the use of carboplatin in combination with paclitaxel for the treatment of relapsed small cell lung cancer	Strong For	Low
Carboplatin (Internal Review)	11/2/12	For the use of carboplatin in combination with etoposide, ifosfamide, and rituximab for relapsed or refractory acute lymphoblastic leukemia	Strong For	Low
Carboplatin (Internal Review)	11/12/12	For the use of carboplatin in combination with etoposide and ifosfamide for stem cell transplant preparation prior to autologous stem cell transplant in relapsed or refractory germ cell tumor	Equivocal/Weak For	Low
Carboplatin (Internal Review)	12/11/12	For the use of carboplatin in combination with bleomycin and etoposide for the treatment of testicular cancer	Equivocal/Weak For	High
Carboplatin (Internal Review)	12/11/12	For the use of carboplatin for the treatment of stage I seminoma	Strong For	Moderate
Carboplatin (Internal Review)	12/17/12	For the use of Carboplatin in combination with etoposide and ifosfamide for poor-risk relapsed Wilms' tumor	Strong For	Very Low
Carboplatin (Internal Review)	12/19/12	For the use of carboplatin, in combination with teniposide, for the treatment of recurrent grade III gliomas	Equivocal/Weak For	Very Low
Carboplatin (Internal Review)	3/17/15	For the use of carboplatin, in combination with vincristine, for the treatment of low-grade gliomas	Equivocal/Weak For	Very Low
Carboplatin (Internal Review)	12/20/12	For the use of carboplatin, in combination with irinotecan and bevacizumab, for the treatment of glioblastoma multiforme after failing prior bevacizumab-based therapy	Equivocal/Weak For	Low
Carboplatin (Internal Review)	7/28/16	For the use of carboplatin and pemetrexed in the treatment of previously untreated, advanced, unresectable malignant pleural mesotheliomas	Equivocal/Weak For	Very Low

Carmustine (Internal Review)	10/14/11	For the use of carmustine for stem-cell transplant preparation prior to allogeneic transplantation for relapsed or refractory lymphoma, in combination with other chemotherapy agents	Equivocal/Weak For	Low
Carmustine (Internal Review)	10/14/11	For the use of carmustine for stem-cell transplant preparation prior to autologous transplant for relapsed, chemotherapy-sensitive Hodgkin's disease, in combination with etoposide, cytarabine, and melphalan	Strong For	Moderate
Carmustine (Internal Review)	10/14/11	For the use of carmustine for stem-cell transplant preparation prior to autologous transplant for relapsed, chemotherapy-sensitive, intermediate- or high-grade non-Hodgkin's lymphoma, in combination with other chemotherapy agents	Strong For	Moderate
Carmustine (Internal Review)	10/14/11	For the use of carmustine for the topical treatment of cutaneous T-cell lymphoma	Equivocal/Weak For	Low
Carmustine (Internal Review)	10/14/11	Against the use of carmustine for the first-line treatment of metastatic melanoma in combination with dacarbazine, cisplatin, and tamoxifen	Strong Against	High
Carfilzomib (Internal Request)	4/22/19	Against the use of carfilzomib, melphalan, prednisone (KMP) for the treatment of newly diagnosed multiple myeloma in patients who are ineligible for autologous stem-cell transplant	Strong Against	Low
Ceritinib (Internal Review)	2/24/17	For the use of ceritinib in the first-line treatment of ALK-positive metastatic non-small lung cancer	Equivocal/Weak For	Moderate
Cetuximab (Internal Review)	10/10/11	For the use of cetuximab in combination with cisplatin for the treatment of recurrent or metastatic squamous cell head and neck cancer	Equivocal/Weak For	High
Cetuximab (Internal Review)	10/10/11	For the use of cetuximab in combination with carboplatin and 5-fluorouracil for the treatment of recurrent or metastatic squamous cell head and neck cancer	Strong For	High
Cetuximab (Internal Review)	10/10/11	For the use of cetuximab in combination with cisplatin with 5-fluorouracil for the treatment of recurrent or metastatic squamous cell head and neck cancer	Strong For	High
Cetuximab (Internal Review)	10/10/11	For the use of cetuximab for the first-line treatment of EGFR-positive advanced non-small cell lung cancer in combination with cisplatin and vinorelbine	Equivocal/Weak For	High
Cetuximab (Internal Review)	6/30/16	For the use of cetuximab in combination with modified FOLFOX6 for the first-line treatment of KRAS wild-type metastatic colorectal cancer	Equivocal/Weak For	Low
Cisplatin (Internal Review)	1/26/12	For the use of cisplatin in combination with cyclophosphamide and doxorubicin for the first-line treatment of unresectable advanced thymoma	Strong For	Low
Cisplatin (Internal Review)	1/26/12	For the use of cisplatin in combination with etoposide and ifosfamide for the first-line treatment of unresectable, advanced thymic carcinoma	Equivocal/Weak For	Very Low
Cisplatin (Internal Review)	1/26/12	For the use of cisplatin in combination with cyclophosphamide, doxorubicin, and vincristine for the first-line treatment of unresectable, advanced thymoma	Equivocal/Weak For	Low
Cisplatin (Internal Review)	1/27/12	For the use of cisplatin in combination with etoposide and ifosfamide for the first-line treatment of unresectable, advanced thymoma	Equivocal/Weak For	Very Low
Cisplatin (Internal Review)	1/27/12	For the use of cisplatin in combination with etoposide for first-line treatment of unresectable, advanced thymoma	Equivocal/Weak For	Low
Cisplatin (Internal Review)	9/14/12	For the use of cisplatin in combination with radiotherapy for the treatment of previously untreated unresectable squamous cell head and neck cancer, excluding cancers of the nasopharynx, paranasal sinus, or parotid gland	Strong For	High
Cisplatin (Internal Review)	9/14/12	For the use of cisplatin in combination with radiotherapy for the treatment of previously untreated resectable squamous cell head and neck cancer of the larynx	Equivocal/Weak For	Moderate

Cisplatin (Internal Review)	9/14/12	For the use of cisplatin in combination with radiotherapy for the treatment of previously untreated squamous cell head and neck cancer of the oral cavity, oropharynx, hypopharynx, or larynx	Strong For	High
Cisplatin (Internal Review)	11/28/12	Against the use of cisplatin for the treatment of advanced hepatocellular cancer	Equivocal/Weak Against	Low
Cisplatin (Internal Review)	12/10/12	For the use of cisplatin in combination with high dose cytarabine and dexamethasone for salvage therapy for non-Hodgkin's lymphoma	Strong For	Low
Cisplatin (Internal Review)	12/11/12	For the use of cisplatin in combination with paclitaxel and ifosfamide for neoadjuvant treatment of locally advanced or metastatic carcinoma of the penis	Strong For	Very Low
Cisplatin (Internal Review)	12/11/12	For the use of cisplatin in combination with methotrexate and bleomycin for the treatment locally advanced or metastatic penile cancer	Strong For	Very Low
Cisplatin (Internal Review)	12/20/12	For the use of cisplatin in combination with etoposide, vincristine, cyclophosphamide, and doxorubicin for the treatment of localized and unresectable neuroblastoma	Strong For	Very Low
Cisplatin (Internal Review)	12/27/12	For the use of cisplatin as first-line treatment of inoperable stage III or IV non-small cell lung cancer, in combination with mitomycin and vinblastine or ifosfamide	Strong For	High
Cladribine (Internal Review)	4/27/12	For the use of cladribine for the treatment of relapsed or refractory cutaneous T-cell lymphoma	Equivocal/Weak For	Very Low
Cladribine (Internal Review)	8/20/12	For the use of cladribine for the first-line treatment of low-grade non-Hodgkin's lymphoma	Equivocal/Weak For	Low
Cladribine (Internal Review)	8/23/12	For the use of cladribine in combination with daunorubicin and cytarabine as induction therapy for previously untreated acute myelogenous leukemia	Equivocal/Weak For	Moderate
Cladribine (Internal Review)	8/28/12	For the use of cladribine in combination with cyclophosphamide for the first-line treatment of chronic lymphocytic leukemia	Equivocal/Weak For	Moderate
Cladribine (Internal Review)	9/4/12	For the use of cladribine in combination with cyclophosphamide and mitoxantrone for the first-line treatment of chronic lymphocytic leukemia	Equivocal/Weak For	Moderate
Cyclophosphamide (Internal Review)	10/18/12	For the use of cyclophosphamide, in combination with doxorubicin and vincristine, for the treatment of newly-diagnosed small-cell lung cancer	Strong For	Moderate
Cyclophosphamide (Internal Review)	10/18/12	For the use of cyclophosphamide, in combination with doxorubicin and etoposide, for the treatment of newly-diagnosed small cell lung cancer	Strong For	High
Cyclophosphamide (Internal Review)	11/13/12	For the use of cyclophosphamide in combination with busulfan for stem cell transplant preparation prior to allogeneic hematopoietic stem cell transplantation	Strong For	High
Cyclophosphamide (Internal Review)	11/13/12	For the use of cyclophosphamide in combination with fludarabine for stem cell transplant preparation prior to non-myeloablative allogeneic hematopoietic stem cell transplantation	Strong For	Low
Cyclophosphamide (Internal Review)	11/13/12	For the use of cyclophosphamide in combination with fludarabine for stem cell transplant preparation prior to reduced intensity allogeneic hematopoietic stem cell transplantation for advanced indolent B cell malignancies	Strong For	Low
Cyclophosphamide (Internal Review)	12/11/12	For the use of cyclophosphamide in combination with granulocyte colony-stimulating factor for peripheral blood stem cell mobilization	Strong For	Moderate
Cyclophosphamide (Internal Review)	12/2/16	For the use of cyclophosphamide in combination with methotrexate and 5-fluorouracil (CMF) for the adjuvant treatment of breast cancer	Weak For	Moderate

Cytarabine (Internal Review)	12/10/12	For the use of cytarabine in combination with other chemotherapy agents for the treatment of relapsed or refractory non-Hodgkin's lymphoma	Strong For	Low
Cytarabine (Internal Review)	10/12/11	For the use of cytarabine for the treatment of relapsed or refractory Hodgkin's disease, in combination with other chemotherapy agents	Strong For	Low
Dabrafenib (External Request - Novartis)	11/6/17	For the use of dabrafenib and trametinib as adjuvant treatment of completely resected stage III melanoma in patients with the BRAF V600 mutation	Weak For	Low
Dabrafenib (Internal Review)	12/28/17	For the use of dabrafenib and trametinib for the treatment of locally advanced or metastatic anaplastic thyroid cancer	Weak For	Very Low
Dacarbazine (Internal Review)	9/25/14	Against the use of dacarbazine for the treatment of carcinomatous meningitis due to melanoma	Strong Against	Very Low
Dacarbazine (Internal Review)	10/13/11	For the use of dacarbazine in combination with mesna, ifosfamide, and doxorubicin for the first-line treatment of unresectable or metastatic soft-tissue sarcoma	Strong For	Moderate
Dacarbazine (Internal Review)	12/27/12	For the use of dacarbazine in combination with mesna, ifosfamide, and doxorubicin for the treatment of unresectable or metastatic osteogenic sarcoma	Equivocal/Weak For	Very Low
Dacarbazine (Internal Review)	10/18/11	For the use of dacarbazine in combination with other chemotherapy agents for the treatment of advanced neuroblastoma	Equivocal/Weak For	Low
Dacarbazine (Internal Review)	12/26/12	For the use of dacarbazine in combination with mesna, ifosfamide, and doxorubicin for the treatment of unresectable or metastatic Ewing's sarcoma	Equivocal/Weak For	Very Low
Dacarbazine (Internal Review)	12/27/12	For the use of dacarbazine in combination with mesna, ifosfamide, and doxorubicin for the treatment of unresectable or metastatic rhabdomyosarcoma	Equivocal/Weak For	Very Low
Dactinomycin (Internal Review)	10/10/11	For the use of dactinomycin for the treatment of Kaposi's sarcoma	Equivocal/Weak For	Very Low
Dactinomycin (Internal Review)	10/14/11	Against the use of dactinomycin for the treatment of malignant melanoma as a single-agent or in combination with other chemotherapy	Equivocal/Weak Against	Very Low
Dactinomycin (Internal Review)	12/14/12	For the use of dactinomycin for the treatment of osteogenic sarcoma	Equivocal/Weak For	Very Low
Daratumumab (Internal Review)				
Daratumumab (Internal Review)				
Daratumumab				
Daratumumab				
Daunorubicin, Liposomal (Internal Review)				
Daunorubicin, Liposomal (Internal Review)				
Daunorubicin, Liposomal (Internal Review)				
Daunorubicin, Liposomal (Internal Review)				



Decitabine (Internal Review)				
Denileukin Diftitox (Internal Review)				
Docetaxel (Internal Review)				
Docetaxel (Internal Review)				
Docetaxel (Internal Review)	10/3/11	breast cancer For the use of docetaxel in combination with cyclophosphamide for the adjuvant treatment of stage I to III invasive breast cancer	Strong For	High
Docetaxel (Internal Review)	10/3/11	For the use of docetaxel for the first-line treatment of metastatic breast cancer	Strong For	Moderate
Docetaxel (Internal Review)	10/3/11	For the use of docetaxel for the adjuvant treatment of operable node-positive or high-risk node-negative (tumor \leq 2 cm) breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy	Strong For	High
Docetaxel (Internal Review)	10/3/11	For the use of docetaxel for the adjuvant treatment of node-positive breast cancer in sequence with fluorouracil, epirubicin, and cyclophosphamide (FEC-D regimen)	Strong For	High
Docetaxel (Internal Review)	10/3/11	For the use of docetaxel for the treatment of advanced gastric cancer as a single-agent	Equivocal/Weak For	Low
Docetaxel (Internal Review)	10/10/11	For the use of docetaxel in combination with carboplatin for the first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer	Strong For	High
Docetaxel (Internal Review)	10/10/11	For the use of docetaxel in combination with gemcitabine for the first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC)	Strong For	High
Docetaxel (Internal Review)	10/14/11	For the use docetaxel of for the treatment of metastatic malignant melanoma	Equivocal/Weak For	Low
Docetaxel (Internal Review)	10/20/11	For the use of docetaxel for the treatment of refractory advanced ovarian cancer	Equivocal/Weak For	Low
Docetaxel (Internal Review)	10/20/11	For the use of docetaxel in combination with carboplatin for the first-line adjuvant treatment of Stage Ic–IV ovarian cancer and peritoneal cancers	Strong For	High
Doxorubicin (Internal Review)	8/24/12	For the use of doxorubicin in combination with vincristine and dexamethasone as induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma	Equivocal/Weak For	Moderate
Doxorubicin (Internal Review)	11/28/12	For the use of doxorubicin in combination with cisplatin for the treatment of advanced stage hepatocellular carcinoma	Equivocal/Weak For	Low
Doxorubicin (Internal Review)	12/26/12	For the use of doxorubicin-eluting beads for the treatment of metastatic liver lesions from malignant melanoma	Equivocal/Weak For	Very Low
Doxorubicin, Liposomal (Internal Review)	10/3/11	For the use of doxorubicin liposomal for the treatment of locally advanced or metastatic breast cancer	Strong For	High
Doxorubicin, Liposomal (Internal Review)	4/27/12	For the use of doxorubicin liposomal for the treatment of refractory or transformed cutaneous T-cell lymphoma	Equivocal/Weak For	Very Low
Durvalumab (Internal Review)	11/7/17	For the use of durvalumab for consolidation treatment of locally advanced or unresectable non-small cell lung cancer (NSCLC) after treatment and response to platinum-based chemoradiotherapy	Strong For	Low
Enzalutamide	6/21/19	For the use of enzalutamide for the first-line treatment of metastatic, hormone-sensitive prostate cancer, in combination with continuous testosterone suppression therapy	Weak For	Moderate

Epirubicin (Internal Review)	1/24/12	For the use of epirubicin as prophylaxis of primary or recurrent stage Ta and/or T1 transitional-cell bladder cancer following transurethral resection	Equivocal/Weak For	Moderate
Epirubicin (Internal Review)	2/1/12	For the use of epirubicin in combination with ifosfamide for the first-line treatment of advanced soft tissue sarcoma	Equivocal/Weak For	Low
Epirubicin (Internal Review)	2/1/12	For the use of epirubicin in combination with ifosfamide for the adjuvant treatment of soft-tissue sarcoma	Equivocal/Weak For	Low
Epirubicin (Internal Review)	3/1/12	Against the use of epirubicin in combination with carboplatin and paclitaxel for the first-line treatment of advanced ovarian cancer	Strong Against	High
Epirubicin (Internal Review)	4/26/12	For the use of epirubicin for the adjuvant treatment of gastric cancer in combination with cisplatin and 5-fluorouracil given sequentially with chemoradiation therapy	Equivocal/Weak For	Low
Epirubicin (Internal Review)	4/26/12	For the use of epirubicin in combination with cisplatin and 5-fluorouracil for the perioperative treatment of gastric cancer	Strong For	High
Epirubicin (Internal Review)	8/20/12	For the use of epirubicin for the treatment of metastatic breast cancer	Equivocal/Weak For	Low
Epirubicin (Internal Review)	8/20/12	For the use of epirubicin in combination with cyclophosphamide for the first-line treatment of metastatic breast cancer	Strong For	Moderate
Epirubicin (Internal Review)	8/20/12	For the use of epirubicin in combination with cyclophosphamide and fluorouracil for the treatment of metastatic breast cancer	Strong For	high
Epirubicin (Internal Review)	8/23/12	For the use of epirubicin in combination with etoposide for the treatment of hepatocellular carcinoma not eligible for surgical or locoregional therapy	Equivocal/Weak For	Very Low
Epirubicin (Internal Review)	8/23/12	Epirubicin for the locoregional treatment of inoperable hepatocellular cancer	Equivocal/Weak For	Low
Epirubicin (Internal Review)	8/24/12	For the use of epirubicin for peripheral blood stem cell mobilization in multiple myeloma, in combination with ifosfamide, and etoposide, and filgrastim	Equivocal/Weak For	Very Low
Epirubicin (Internal Review)	8/29/12	Epirubicin for the treatment of relapsed or refractory multiple myeloma, in combination with other chemotherapy agent	Equivocal/Weak For	Low
Erlotinib (Internal Review)	10/10/11	Against the use of erlotinib for the treatment of recurrent or metastatic squamous cell head and neck cancer	Equivocal/Weak Against	Low
Estramustine (Internal Review)	10/12/11	For the use of docetaxel in combination with estramustine for the treatment of hormone-refractory, metastatic prostate cancer	Equivocal/Weak For	High
Etoposide (Internal Review)	9/17/12	For the use of etoposide as part of the Stanford V for the treatment of locally extensive and advanced-stage Hodgkin's lymphoma	Equivocal/Weak For	Moderate
Etoposide (Internal Review)	9/17/12	For the use of etoposide as part of the BEACOPP for the treatment of advanced-stage Hodgkin's lymphoma	Strong For	High
Etoposide (Internal Review)	9/20/12	For the use of etoposide in combination with mitoxantrone and cytarabine in the treatment of refractory acute myeloid leukemia	Equivocal/Weak For	Low
Etoposide (Internal Review)	10/3/12	For the use of etoposide in combination with cisplatin and concurrent radiotherapy for stage IIIB non-small cell lung cancer	Strong For	Moderate
Etoposide (Internal Review)	10/3/12	For the use of etoposide in combination with cisplatin for the treatment of resected stage IB-III non-small cell lung cancer	Strong For	High
Etoposide (Internal Review)	11/2/12	For the use of etoposide in combination with clofarabine and cyclophosphamide in the treatment of relapsed or refractory acute lymphoblastic leukemia	Equivocal/Weak For	Low
Etoposide (Internal Review)	11/2/12	For the use of etoposide in combination with total body irradiation for allogeneic hematopoietic stem cell transplantation	Strong For	High
Etoposide (Internal Review)	11/13/12	For the use of etoposide in combination with mitomycin/doxorubicin/cisplatin/ifosfamide for the treatment of refractory fibromatosis/desmoid tumor	Equivocal/Weak For	Very Low

Etoposide (Internal Review)	12/15/12	For the use of etoposide in combination with methotrexate, dactinomycin, cyclophosphamide and vincristine (EMA-CO) for high-risk gestational trophoblastic disease	Strong For	Low
Etoposide (Internal Review)	12/15/12	For the use of etoposide in combination with methotrexate, dactinomycin and cisplatin (EMA-EP) for high-risk gestational trophoblastic disease	Equivocal/Weak For	Very Low
Etoposide (Internal Review)	12/20/12	For the use of etoposide in combination with carboplatin, cyclophosphamide, and doxorubicin for the treatment of intermediate-risk neuroblastoma	Strong For	Low
Everolimus (External Request - Novartis Pharmaceuticals Corp)	10/17/17	For the use of everolimus in combination with vinorelbine and trastuzumab for the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients who have received prior taxane chemotherapy	Equivocal/Weak For	Moderate
Everolimus (External Request - Novartis Pharmaceuticals Corp)	11/14/11	For the use of everolimus for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex in pediatric patients less than 3 years of age who require therapeutic intervention but are not candidates for curative surgical resection	Equivocal/Weak For	Low
Everolimus (External Request - Novartis Pharmaceuticals Corp)	12/19/14	For the use of everolimus in combination with exemestane for the treatment of estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in postmenopausal women refractory to letrozole or anastrozole	Strong For	High
Everolimus (External Request - Novartis Pharmaceuticals Corp)	11/15/11	For the use of everolimus in combination with tamoxifen for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women with secondary aromatase inhibitor resistance	Strong For	Low
Everolimus (Internal Review)	7/11/16	For the use of everolimus for the treatment of relapsed or refractory Waldenstrom macroglobulinemia	Equivocal/Weak For	Low
Finasteride (Internal Review)	10/21/11	Against the use of finasteride for prostate cancer prophylaxis	Strong Against	High
Floxuridine (Internal Review)	10/12/11	For the use of floxuridine for the treatment of unresectable hepatocellular cancer, in combination with radiotherapy	Equivocal/Weak For	Low
Fludarabine (Internal Review)	4/27/12	For the use of fludarabine for the treatment of advanced cutaneous T-cell lymphoma	Equivocal/Weak For	Very Low
Fludarabine (Internal Review)	8/24/12	For the use of fludarabine for the treatment of prolymphocytic leukemia (PLL)	Equivocal/Weak For	Very Low
Fludarabine (Internal Review)	9/20/12	For the use of fludarabine in combination with cytarabine and G-CSF for the treatment of refractory or relapsed acute myeloid leukemia	Equivocal/Weak For	Low
Fluorouracil,5-FU (Internal Review)	9/14/12	For the use of fluorouracil in combination with carboplatin for the treatment of recurrent or metastatic squamous cell head and neck cancer	Equivocal/Weak For	Moderate
Fluorouracil,5-FU (Internal Review)	9/14/12	For the use of fluorouracil in combination with cisplatin for the treatment of advanced or recurrent head and neck cancer	Equivocal/Weak For	Moderate
Fluorouracil,5-FU (Internal Review)	9/14/12	For the use of fluorouracil in combination with cisplatin and radiotherapy for the treatment of advanced nasopharyngeal head and neck cancer	Strong For	Moderate
Fluorouracil,5-FU (Internal Review)	9/14/12	For the use of fluorouracil in combination with carboplatin and radiotherapy for the treatment of advanced stage head and neck cancer	Equivocal/Weak For	High
Fluorouracil,5-FU (Internal Review)	11/26/14	For the use of 5-fluorouracil, in combination with cisplatin and radiation, for the treatment of anal cancer	Equivocal/Weak For	High
Gefitinib (Internal Review)	10/10/11	Against the use of gefitinib for the treatment of recurrent or metastatic squamous-cell head and neck cancer	Strong Against	High
Gemcitabine (Internal Review)	10/11/17	For the use of gemcitabine, cisplatin, prednisone, and thalidomide for the first-line treatment of peripheral T-cell lymphoma	Weak For	Low

Gemcitabine (Internal Review)	10/25/11	For the use of gemcitabine in combination with cisplatin for the treatment of advanced or metastatic biliary tract cancer	Strong For	High
Gemcitabine (Internal Review)	1/25/12	For the use of gemcitabine in combination with cisplatin for the first-line treatment of locally advanced or metastatic transitional-cell bladder cancer	Strong For	High
Gemcitabine (Internal Review)	4/27/12	For the use of gemcitabine for the treatment of advanced cutaneous T-cell lymphoma	Equivocal/Weak For	Very Low
Gemcitabine (Internal Review)	8/24/12	For the use of gemcitabine in combination with carboplatin for the first-line treatment of inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)	Strong For	Moderate
Gemcitabine (Internal Review)	8/29/12	For the use of gemcitabine for the treatment of metastatic breast cancer as a single-agent	Strong For	Low
Gemcitabine (Internal Review)	9/11/12	For the use of gemcitabine for the treatment of recurrent ovarian cancer as a single agent	Equivocal/Weak For	Moderate
Gemcitabine (Internal Review)	9/12/12	For the use of gemcitabine in combination with cisplatin or carboplatin for the treatment of malignant mesothelioma	Equivocal/Weak For	Low
Gemcitabine (Internal Review)	9/12/12	For the use of gemcitabine for the treatment of relapsed malignant mesothelioma as a single-agent	Equivocal/Weak For	Very Low
Gemcitabine (Internal Review)	12/27/12	For the use of gemcitabine for the adjuvant treatment of pancreatic cancer	Strong For	Moderate
Gemcitabine (Internal Review)	5/26/16	For the use of gemcitabine, dexamethasone, and cisplatin (and rituximab for CD20-positive disease) for the treatment of relapsed or refractory, aggressive non-Hodgkin lymphoma (NHL) in transplant eligible patients	Strong For	Moderate
Gemcitabine (Internal Review)	11/20/17	For the use of gemcitabine plus capecitabine for the adjuvant treatment of pancreatic ductal adenocarcinoma	Strong For	Moderate
Granisetron Extended Release (External Request - Heron Therapeutics, Inc.)	10/5/16	For the use of extended-release granisetron for chemotherapy-induced nausea/vomiting prophylaxis, in combination with fosaprepitant and dexamethasone	Weak For	Moderate
Hydroxyurea (Internal Review)	10/3/11	Against the use of hydroxyurea for the treatment of acute myelogenous leukemia, in elderly patients not fit for intensive treatment	Strong Against	Moderate
Hydroxyurea (Internal Review)	10/3/11	For the use of hydroxyurea to lower peripheral blast counts prior to induction therapy in patients with acute myeloid leukemia	Strong For	Very Low
Hydroxyurea (Internal Review)	10/10/11	Against the use of hydroxyurea in combination with chemotherapy for the treatment of advanced non-small cell lung cancer	Equivocal/Weak Against	Low
Hydroxyurea (Internal Review)	10/19/11	Against the use of hydroxyurea in combination with procarbazine for the adjuvant treatment of pediatric patients with medulloblastoma	Equivocal/Weak Against	Very Low
Hydroxyurea (Internal Review)	10/23/11	For the use of hydroxyurea as part of the 8-in-1 regimen for the adjuvant treatment of pediatric patients with primitive neuroectodermal tumor	Equivocal/Weak For	Low
Ibrutinib (Internal Review)	8/3/18	For the use of ibrutinib and rituximab for the treatment of Waldenstrom macroglobulinemia	Equivocal/Weak For	Moderate
Idarubicin (Internal Review)	10/3/11	For the use of idarubicin in combination with cytarabine or imatinib and cytarabine for the treatment of myeloid blast crisis chronic myelogenous leukemia	Equivocal/Weak For	Low
Idarubicin (Internal Review)	10/3/11	For the use of idarubicin in combination with chemotherapy for the treatment of relapsed or refractory Non-Hodgkin's lymphoma	Equivocal/Weak For	Low

Idarubicin (Internal Review)	10/17/11	For the use of idarubicin in combination with cytarabine as induction therapy in relapsed or refractory acute lymphocytic leukemia	Equivocal/Weak For	Low
Idelalisib, bendamustine, rituximab (Internal Review)	4/14/17	For the use of idelalisib in combination with bendamustine and rituximab for the treatment of relapsed or refractory chronic lymphocytic leukemia	Equivocal/Weak For	Moderate
Ifosfamide (Internal Review)	11/27/12	For the use of ifosfamide for the treatment of previously treated bladder cancer	Equivocal/Weak For	Very Low
Ifosfamide (Internal Review)	11/27/12	Against the use of ifosfamide in combination with gemcitabine for the treatment of recurrent bladder cancer	Equivocal/Weak Against	Low
Ifosfamide (Internal Review)	11/27/12	For the use of ifosfamide in combination with gemcitabine for the treatment of recurrent bladder cancer	Equivocal/Weak For	Very Low
Ifosfamide (Internal Review)	12/10/12	For the use of ifosfamide in combination with carboplatin and etoposide for the treatment of relapsed or refractory non-Hodgkin's lymphoma	Equivocal/Weak For	Low
Ifosfamide (Internal Review)	12/10/12	For the use of ifosfamide in combination with rituximab, carboplatin and etoposide for the treatment of relapsed or refractory CD20+ diffuse large B-cell non-Hodgkin's lymphoma	Equivocal/Weak For	Low
Ifosfamide (Internal Review)	12/4/12	For the use of ifosfamide in combination with vincristine, doxorubicin and etoposide followed by ifosfamide in combination with vincristine and actinomycin D for newly-diagnosed Ewing's sarcoma	Equivocal/Weak For	Very Low
Ifosfamide (Internal Review)	12/17/12	For the use of ifosfamide, in combination with carboplatin and etoposide for the treatment of recurrent or refractory Ewing's sarcoma	Equivocal/Weak For	Very Low
Ifosfamide (Internal Review)	12/17/12	For the use of ifosfamide, in combination with carboplatin and etoposide followed by cyclophosphamide, doxorubicin and vincristine for the treatment of newly-diagnosed Ewing's sarcoma	Equivocal/Weak For	Very Low
Ifosfamide (Internal Review)	12/26/12	For the use of ifosfamide plus etoposide, alternating with vincristine plus doxorubicin plus cyclophosphamide for the treatment of newly-diagnosed Ewing's sarcoma family tumors	Strong For	Low
Ifosfamide (Internal Review)	12/26/12	For the use of high-dose ifosfamide alone for the treatment of recurrent or refractory Ewing's sarcoma	Equivocal/Weak For	Very Low
Ifosfamide (Internal Review)	12/27/12	For the use of ifosfamide, in combination with vincristine, dactinomycin, and doxorubicin for the first-line treatment of rhabdomyosarcoma in children and adolescents	Strong For	Low
Imatinib (Internal Review)	10/12/11	For the use of imatinib mesylate for the treatment of desmoid tumor or fibromatosis not amenable to surgery or radiotherapy	Equivocal/Weak For	Low
Interferon Alfa-2a (Internal Review)	4/27/12	For the use of interferon alfa-2a for the treatment of cutaneous T-cell lymphoma	Equivocal/Weak For	Very Low
Interferon Alfa-2b (Internal Review)	8/24/12	For the use of interferon alfa-2b as maintenance therapy for multiple myeloma	Equivocal/Weak For	Moderate
Interferon Alfa-2b (Internal Review)	8/24/12	For the use of interferon alfa-2b in combination with cytarabine for the first-line treatment of Philadelphia chromosome positive, chronic phase, chronic myelogenous leukemia	Equivocal/Weak For	Moderate
Interferon Alfa-2b (Internal Review)	12/27/12	For the use of interferon alfa-2b in combination with zidovudine for the treatment of T-cell lymphoma/leukemia associated with human T-lymphotropic virus type I (HTLV-1)	Equivocal/Weak For	Very Low
Ipilimumab	9/20/13	For the use of ipilimumab in combination with dacarbazine for the first-line treatment of metastatic malignant melanoma	Equivocal/Weak For	Moderate

Ipilimumab	3/13/15	For the use of ipilimumab plus sargramostim for the treatment of unresectable or metastatic malignant melanoma following no more than 1 prior therapy	Equivocal/Weak For	Very Low
Irinotecan (Internal Review)	2/1/12	For the use of irinotecan in combination with chemotherapy for the treatment of previously untreated metastatic rhabdomyosarcoma	Equivocal/Weak For	Very Low
Irinotecan (Internal Review)	2/1/12	For the use of irinotecan in combination with chemotherapy for rhabdomyosarcoma in patients in first relapse or with disease progression	Equivocal/Weak For	Low
Irinotecan (Internal Review)	3/1/12	For the use of irinotecan monotherapy for the treatment of recurrent malignant glioma	Equivocal/Weak For	Low
Irinotecan (Internal Review)	10/3/12	For the use of irinotecan in combination with cisplatin for the treatment of extensive small cell lung cancer	Equivocal/Weak For	Low
Irinotecan (Internal Review)	10/3/12	For the use of irinotecan in combination with cisplatin for the treatment of advanced non-small cell lung cancer	Strong For	Moderate
Irinotecan (Internal Review)	12/5/12	For the use of irinotecan in combination with fluorouracil for previously untreated advanced gastric cancer	Equivocal/Weak For	Moderate
Irinotecan (Internal Review)	12/5/12	For the use of irinotecan in combination with cisplatin for resectable locally advanced gastric cancer	Equivocal/Weak For	Very Low
Irinotecan (Internal Review)	12/5/12	For the use of irinotecan in combination with capecitabine as second line treatment of advanced gastric cancer	Equivocal/Weak For	Very Low
Irinotecan (Internal Review)	12/27/12	For the use of irinotecan in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of metastatic pancreatic cancer	Equivocal/Weak For	Moderate
Isotretinoin (Internal Review)	10/3/11	For the use of isotretinoin for the treatment of juvenile chronic myelogenous leukemia	Equivocal/Weak For	Very Low
Isotretinoin (Internal Review)	10/10/11	For the use of isotretinoin in combination with interferon alfa and vitamin E for the adjuvant treatment of advanced squamous cell head and neck cancer	Equivocal/Weak For	Low
Isotretinoin (Internal Review)	10/18/11	Against the use of isotretinoin in combination with interferon alfa for the treatment of recurrent cervical cancer	Equivocal/Weak Against	Low
Isotretinoin (Internal Review)	10/18/11	For the use of isotretinoin following autologous bone marrow transplantation in pediatric patients with high-risk neuroblastoma	Strong For	Moderate
Isotretinoin (Internal Review)	10/21/11	Against the use of isotretinoin in combination with interferon alfa for the adjuvant treatment of aggressive squamous cell skin carcinoma	Strong Against	Moderate
Ixazomib (Internal Review)	2/27/19	For the use of ixazomib as maintenance therapy following autologous stem-cell transplantation in adult patients with multiple myeloma	Weak For	Moderate
Lenalidomide (Internal Review)	2/26/15	For the use of lenalidomide in combination with rituximab for the treatment of newly diagnosed multiple myeloma	Strong For	Low
Lenalidomide (Internal Review)	10/20/16	For the use of lenalidomide, melphalan, and dexamethasone for the treatment of systemic amyloid light-chain amyloidosis	Weak For	Very Low
Lenalidomide (Internal Review)	10/20/16	For the use of lenalidomide, cyclophosphamide, and dexamethasone for the treatment of systemic amyloid light-chain amyloidosis	Weak For	Low
Leuprolide (Internal Review)	10/3/11	For the use of leuprolide for the treatment of premenopausal women with hormone receptor-positive breast cancer	Equivocal/Weak For	Moderate
Lomustine (Internal Review)	10/3/11	Against the use of lomustine for the treatment of non-Hodgkin's lymphoma, in combination with other chemotherapy agents	Equivocal/Weak Against	Very Low
Lomustine (Internal Review)	10/14/11	For the use of lomustine for the treatment of metastatic melanoma, in combination with dacarbazine-containing chemotherapy	Equivocal/Weak For	Low
Megestrol (Internal Review)	10/12/11	Against the use of megestrol acetate for the treatment of metastatic renal cell cancer	Equivocal/Weak Against	Low

Megestrol (Internal Review)	10/12/11	Against the use of megestrol acetate for the treatment of advanced hormone-refractory prostate cancer	Equivocal/Weak Against	Low
Melphalan (Internal Review)	9/17/12	For the use of melphalan in combination with fludarabine as conditioning for reduced intensity allogeneic stem cell transplantation in the treatment of hematologic malignancies	Equivocal/Weak For	Low
Melphalan (Internal Review)	11/12/12	For the use of melphalan as stem cell transplant preparation prior to tandem autologous stem cell transplantation in the treatment of newly diagnosed multiple myeloma	Strong For	Moderate
Melphalan (Internal Review)	11/13/12	For the use of melphalan and high dose dexamethasone for the treatment of patients with primary amyloidosis who are ineligible for stem cell transplantation	Equivocal/Weak For	Low
Melphalan (Internal Review)	11/13/12	For the use of melphalan and autologous stem cell transplantation for the treatment of primary systemic amyloidosis	Equivocal/Weak For	Very Low
Mercaptopurine (Internal Review)	10/3/11	Against the use of mercaptopurine in combination with other chemotherapeutic agents as maintenance therapy in acute myelogenous leukemia	Strong Against	Moderate
Mercaptopurine (Internal Review)	10/3/11	Against the use of mercaptopurine for the treatment of chronic myelogenous leukemia	Equivocal/Weak Against	Very Low
Methotrexate (Internal Review)	10/12/11	For the treatment of methotrexate in combination with vinblastine for the treatment of desmoid tumor or aggressive fibromatosis not amenable to surgery or radiotherapy	Equivocal/Weak For	Low
Methotrexate (Internal Review)	10/13/11	For the use of methotrexate for the treatment of carcinomatous meningitis	Strong For	Moderate
Methotrexate (Internal Review)	10/18/11	For the use of methotrexate in combination with other chemotherapy agents as neoadjuvant treatment for muscle-invasive bladder cancer	Equivocal/Weak For	High
Methotrexate (Internal Review)	10/18/11	For the use of vinblastine in combination with other chemotherapy agents for the neoadjuvant treatment of muscle-invasive bladder cancer	Equivocal/Weak For	High
Methotrexate (Internal Review)	10/18/11	For the use of methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line chemotherapy for the treatment of advanced or metastatic bladder cancer	Strong For	High
Mitomycin C (Internal Review)	9/12/12	For the use of mitomycin C for the treatment of malignant mesothelioma administered locally in the pleural cavity in combination with cisplatin	Equivocal/Weak For	Very Low
Mitomycin C (Internal Review)	9/12/12	For the use of mitomycin C in combination with cisplatin for the treatment of malignant peritoneal mesothelioma	Strong For	Low
Mitomycin C (Internal Review)	11/13/12	For the use of mitomycin in combination with cisplatin, doxorubicin, ethiodol and polyvinyl alcohol for unresectable intrahepatic cholangiocarcinoma	Equivocal/Weak For	Very Low
Mitomycin C (Internal Review)	11/13/12	For the use of mitomycin for the treatment of unresectable intrahepatic cholangiocarcinoma	Equivocal/Weak For	Very Low
Mitomycin C (Internal Review)	11/26/14	For the use of mitomycin in combination with fluorouracil and radiation for the treatment of anal cancer	Strong For	Moderate
Mitomycin C (Internal Review)	11/27/12	For the use of mitomycin for the adjuvant treatment of superficial bladder cancer in patients at high risk for recurrence	Strong For	Moderate
Mitomycin C (Internal Review)	11/28/12	For the use of mitomycin C in combination with cisplatin for the treatment of disseminated squamous cell carcinoma of the cervix	Equivocal/Weak For	Low
Mitomycin C (Internal Review)	12/3/12	For the use of mitomycin in combination with fluorouracil and radiation for the treatment of advanced head and neck cancer	Equivocal/Weak For	Moderate
Mitomycin C (Internal Review)	12/5/12	For the use of mitomycin for the treatment of peritoneal carcinomatosis of colorectal cancer	Equivocal/Weak For	Low

Mitomycin C (Internal Review)	12/5/12	For the use of mitomycin for in combination with fluorouracil, and etidodol for the treatment of liver metastases from colorectal cancer	Equivocal/Weak For	Very Low
Mitoxantrone (Internal Review)	9/20/12	For the use of mitoxantrone in combination with cladribine, cytarabine and G-CSF for the treatment of refractory and relapsed acute myelogenous leukemia	Equivocal/Weak For	Low
Mitoxantrone (Internal Review)	11/2/12	For the use of mitoxantrone in combination with ifosfamide and etoposide for the treatment of relapsed and refractory acute lymphoblastic leukemia	Equivocal/Weak For	Very Low
Mitoxantrone (Internal Review)	11/12/12	For the use of mitoxantrone in combination with melphalan for autologous stem cell transplant preparation for the treatment of relapsed/refractory lymphoma	Equivocal/Weak For	Very Low
Mitoxantrone (Internal Review)	11/28/12	For the use of mitoxantrone for the treatment of previously treated metastatic breast cancer	Equivocal/Weak For	Low
Mitoxantrone (Internal Review)	11/28/12	For the use of mitoxantrone in combination with fluorouracil and cisplatin for the treatment of metastatic hepatocellular carcinoma	Equivocal/Weak For	Very Low
Mitoxantrone (Internal Review)	12/11/12	For the use of mitoxantrone in combination with ifosfamide, etoposide, and rituximab for the treatment of relapsed or refractory non-Hodgkin's lymphoma	Equivocal/Weak For	Very Low
Mitoxantrone (Internal Review)	12/11/12	For the use of mitoxantrone in combination with cyclophosphamide and vincristine for the treatment of intermediate or high grade non-Hodgkin's lymphoma	Equivocal/Weak For	Moderate
Mitoxantrone (Internal Review)	12/11/12	For the use of mitoxantrone for the treatment of malignant pleural effusion	Equivocal/Weak For	Very Low
Nelarabine (Internal Review)	10/10/11	Against the use of nelarabine for the treatment of relapsed or refractory chronic lymphocytic leukemia	Equivocal/Weak Against	Very Low
Nelarabine (Internal Review)	10/20/11	For the use of nelarabine for the treatment of T-cell leukemia/lymphoma in patients at first relapse or with refractory disease	Equivocal/Weak For	Very Low
Nivolumab (Internal Review)	10/18/17	For the use of nivolumab for the adjuvant treatment of completely resected stage IIIB to IV melanoma	Equivocal/Weak For	Low
Nivolumab (Internal Review)	9/3/15	For the use of nivolumab for the treatment of unresectable or metastatic malignant melanoma in previously untreated patients without a BRAF mutation	Strong For	Moderate
Nivolumab (Internal Review)	9/3/15	For the use of nivolumab plus ipilimumab for the treatment of unresectable or metastatic malignant melanoma in previously untreated patients	Equivocal/Weak For	Moderate
Nivolumab (Internal Review)	10/26/16	For the use of nivolumab for the treatment of head and neck cancer (squamous cell) with disease progression on or after platinum-containing chemotherapy	Equivocal/Weak For	Low
Ofatumumab (Internal Review)	2/1/17	For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with DHAP	Equivocal/Weak For	Low
Ofatumumab (Internal Review)	10/10/11	For the use of ofatumumab for the treatment of fludarabine-refractory chronic lymphocytic leukemia with bulky lymphadenopathy	Strong For	Low
Olaparib (Internal Review)	10/12/17	For the treatment of HER2-negative, germline BRCA mutated metastatic breast cancer	Weak For	Moderate
Oxaliplatin (Internal Review)	1/2/12	For the treatment of oxaliplatin in combination with gemcitabine for the treatment of advanced or metastatic biliary tract cancer	Equivocal/Weak For	Low
Oxaliplatin (Internal Review)	1/2/12	For the use of oxaliplatin for the treatment of advanced ovarian cancer	Equivocal/Weak For	Moderate
Oxaliplatin (Internal Review)	1/2/12	For the use of oxaliplatin in combination with cytarabine and dexamethasone, with or without rituximab, for the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL)	Equivocal/Weak For	Very Low
Oxaliplatin (Internal Review)	1/9/12	For the use of oxaliplatin in combination with irinotecan and 5-fluorouracil-based chemotherapy for the first-line treatment of metastatic colorectal cancer	Strong For	Moderate

Oxaliplatin (Internal Review)	1/9/12	For the use of oxaliplatin in combination with 5-fluorouracil-based chemotherapy for the treatment of advanced or metastatic breast cancer	Equivocal/Weak For	Low
Oxaliplatin (Internal Review)	1/9/12	For the use of oxaliplatin in combination with gemcitabine for the treatment of malignant pleural mesothelioma	Equivocal/Weak For	Low
Oxaliplatin (Internal Review)	1/12/12	For the use of oxaliplatin and epirubicin in combination capecitabine or 5-fluorouracil for the treatment of advanced gastric cancer	Strong For	Moderate
Oxaliplatin (Internal Review)	1/12/12	For the use of oxaliplatin in combination with 5-fluorouracil for the treatment of advanced gastric cancer	Strong For	Moderate
Oxaliplatin (Internal Review)	1/13/12	For the use of oxaliplatin in combination with 5-fluorouracil-based chemotherapy for the treatment of recurrent, advanced head and neck cancer	Equivocal/Weak For	Low
Oxaliplatin (Internal Review)	1/13/12	For the use of oxaliplatin for the treatment of relapsed or refractory germ cell tumor (testicular cancer)	Equivocal/Weak For	Very Low
Oxaliplatin (Internal Review)	12/27/12	For the use of oxaliplatin in combination with gemcitabine for the first-line treatment of locally advanced and metastatic pancreatic cancer	Equivocal/Weak For	High
Oxaliplatin (Internal Review)	12/27/12	For the use of oxaliplatin in combination with 5-fluorouracil-based chemotherapy for the second-line treatment of gemcitabine-refractory advanced pancreatic cancer	Strong For	Low
Paclitaxel (Internal Review)	1/24/12	For the use of paclitaxel in combination with carboplatin for the first-line treatment of advanced transitional-cell bladder cancer	Equivocal/Weak For	Moderate
Paclitaxel (Internal Review)	1/25/12	For the use of paclitaxel in combination with carboplatin for the first-line treatment of unresectable, advanced thymic carcinoma	Equivocal/Weak For	Very Low
Paclitaxel (Internal Review)	1/25/12	For the use of paclitaxel in combination with carboplatin for the first-line treatment of unresectable, advanced thymoma	Equivocal/Weak For	Very Low
Paclitaxel (Internal Review)	1/27/12	For the use of paclitaxel in combination with cisplatin for the treatment of unresectable or metastatic squamous cell esophageal cancer	Equivocal/Weak For	Low
Paclitaxel (Internal Review)	4/3/12	For the use of paclitaxel in combination with doxorubicin and cisplatin for the treatment of advanced or recurrent endometrial cancer	Strong For	High
Paclitaxel (Internal Review)	4/3/12	For the use of paclitaxel for the treatment of relapsed small cell lung cancer as a single-agent	Equivocal/Weak For	Low
Paclitaxel (Internal Review)	8/24/12	For the use of paclitaxel in combination with carboplatin for the treatment of advanced or metastatic non-small cell lung cancer	Strong For	High
Paclitaxel (Internal Review)	8/24/12	For the use of paclitaxel in combination with gemcitabine for the treatment of advanced or metastatic non-small cell lung cancer	Strong For	High
Paclitaxel (Internal Review)	9/11/12	For the use of paclitaxel in combination with carboplatin for the first-line treatment of advanced ovarian cancer	Strong For	Moderate
Paclitaxel (Internal Review)	9/11/12	For the use intraperitoneal paclitaxel in combination with intraperitoneal cisplatin and intravenous paclitaxel for the first-line treatment of ovarian cancer	Strong For	High
Paclitaxel (Internal Review)	9/14/12	For the use of paclitaxel for peripheral blood stem cell mobilization in hematologic malignancies	Equivocal/Weak For	Very Low
Paclitaxel (Internal Review)	9/14/12	For the use of paclitaxel in combination with carboplatin and radiotherapy for the treatment of advanced squamous cell head and neck cancer	Equivocal/Weak For	Low
Paclitaxel, albumin-bound(NAB-Paclitaxel) (External Request - Abraxis BioScience)	12/11/12	For the use of nab-paclitaxel in combination with carboplatin for the first-line treatment of non-small cell lung cancer	Equivocal/Weak For	Very Low

Paclitaxel, albumin-bound(NAB-Paclitaxel) (External Request - Abraxis BioScience)	11/25/13	For the use of nab-paclitaxel in combination with gemcitabine for the first-line treatment of advanced pancreatic cancer	Strong For	Moderate
Paclitaxel, albumin-bound(NAB-Paclitaxel) (Internal Review)	10/3/11	For the use of nanoparticle albumin-bound paclitaxel for the treatment of previously untreated metastatic breast cancer	Equivocal/Weak For	Low
Paclitaxel, albumin-bound(NAB-Paclitaxel) (Internal Review)	10/3/11	For the use of nanoparticle albumin-bound paclitaxel for the treatment of taxane-refractory metastatic breast cancer	Equivocal/Weak For	Low
Panobinostat (External Request - Novartis Pharmaceuticals Corporation)	7/9/15	For the use of panobinostat for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least 2 prior systemic therapies	Equivocal/Weak For	Very Low
Pazopanib (Internal Review)	12/28/17	For the use of pazopanib for the treatment of unresectable, locally advanced, or metastatic gastrointestinal stromal tumors (GIST), after progression on or intolerance to both imatinib and sunitinib	Equivocal/Weak For	Low
Pembrolizumab (Internal Review)	8/17/15	For the use of pembrolizumab for the treatment of unresectable or metastatic malignant melanoma in patients who have disease progression following no more than 1 prior therapy and have not received treatment with a CTLA-4 inhibitor or a PD-1 or PD-L1 inhibitor	Equivocal/Weak For	Low
Pembrolizumab (Internal Review)	6/23/16	For the use of pembrolizumab for the treatment of recurrent locoregional or metastatic Merkel-cell carcinoma in patients who had progressive disease following standard therapy with surgery and/or radiation therapy	Equivocal/Weak For	Very Low
Pembrolizumab (Internal Review)	8/18/16	For the use of pembrolizumab for the treatment of classical Hodgkin's disease that has relapsed or progressed after an autologous stem cell transplant and post-transplant brentuximab vedotin	Equivocal/Weak For	Very Low
Pembrolizumab (Internal Review)	4/14/17	For the use of pembrolizumab for the treatment of advanced urothelial cancer with progression during or after platinum-based chemotherapy	Equivocal/Weak For	Low
Pembrolizumab (Internal Review)	6/1/18	For the use of pembrolizumab for the adjuvant treatment of completely resected, high-risk stage III melanoma	Equivocal/Weak For	Low
Pembrolizumab (Internal Review)	4/4/19	For the use of pembrolizumab plus axitinib for the first-line treatment of advanced renal cell cancer	Strong For	Moderate
Pemetrexed (Internal Review)	2/29/12	For the use of pemetrexed for the treatment of metastatic breast cancer	Equivocal/Weak For	Low
Pemetrexed (Internal Review)	2/29/12	For the use of pemetrexed for the treatment of advanced gastric cancer	Equivocal/Weak For	Low
Pemetrexed (Internal Review)	3/1/12	Against the use of pemetrexed in combination with gemcitabine for the treatment of unresectable locally advanced or metastatic pancreatic cancer	Strong Against	High
Pemetrexed (Internal Review)	3/1/12	For the use of pemetrexed in combination with carboplatin for the first-line treatment of stage IIIB or IV non-small cell lung cancer (NSCLC)	Strong For	Moderate
Pemetrexed (Internal Review)	3/1/12	For the use of pemetrexed for the treatment of advanced unresectable squamous cell head and neck cancer	Equivocal/Weak For	Low
Pentostatin (Internal Review)	4/27/12	For the use of pentostatin for the treatment of advanced cutaneous T-cell lymphoma	Equivocal/Weak For	Very Low
Pentostatin (Internal Review)	11/12/12	For the use of pentostatin in combination with extracorporeal photopheresis and reduced dose total body irradiation for stem cell transplant preparation prior to allogeneic stem cell transplantation	Equivocal/Weak For	Low
Pentostatin (Internal Review)	12/7/12	For the use of pentostatin for the treatment of corticosteroid-refractory acute graft-versus-host disease	Equivocal/Weak For	Very Low
Pentostatin (Internal Review)	12/7/12	For the use of pentostatin for the treatment of corticosteroid-refractory chronic graft-versus-host disease	Equivocal/Weak For	Low

Pentostatin (Internal Review)	12/7/12	For the use of pentostatin in combination with mini-methotrexate and tacrolimus for graft-versus-host disease prophylaxis in stem cell transplantation	Equivocal/Weak For	Low
Pentostatin (Internal Review)	8/28/12	For the use of pentostatin in combination with cyclophosphamide and rituximab for the treatment of chronic lymphocytic leukemia	Equivocal/Weak For	Low
Pomalidomide (Internal Review)	7/11/19	For the use of pomalidomide in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in patients who have received 1 to 3 prior therapies including lenalidomide	Equivocal/Weak For	Low
Ponatinib (Internal Review)	6/30/16	For the use of ponatinib for the treatment of newly diagnosed, chronic phase chronic myelogenous leukemia	Strong/Against	Low
Porfimer Sodium (Internal Review)	10/18/11	For the use of porfimer for the treatment of resistant or refractory superficial bladder cancer	Equivocal/Weak For	Very Low
Procarbazine (Internal Review)	10/3/11	For the use of procarbazine in combination with cyclophosphamide, etoposide, and prednisone for the treatment of recurrent non-Hodakin's lymphoma	Equivocal/Weak For	Low
Procarbazine (Internal Review)	10/10/11	Against the use of procarbazine in combination with cyclophosphamide, doxorubicin, and methotrexate for the first-line treatment of advanced non-small cell lung cancer	Equivocal/Weak Against	Low
Procarbazine (Internal Review)	10/14/11	For the use of procarbazine in combination with cyclophosphamide and antithymocyte globulin for stem cell transplant preparation prior to allogeneic transplantation in patients with severe aplastic anemia	Equivocal/Weak For	Low
Procarbazine (Internal Review)	10/18/11	For the use of procarbazine in combination with chemotherapy for the adjuvant treatment of pediatric patients with high-grade malignant gliomas including astrocytoma	Equivocal/Weak For	Moderate
Procarbazine (Internal Review)	10/18/11	For the use of procarbazine in combination with lomustine and vincristine for the adjuvant treatment of high-grade malignant gliomas	Equivocal/Weak For	High
Procarbazine (Internal Review)	10/18/11	For the use of hydroxyurea as part of the 8-in-1 regimen for the adjuvant treatment of pediatric patients with high-grade malignant glioma	Equivocal/Weak For	Moderate
Procarbazine (Internal Review)	10/19/11	For the use of procarbazine in combination with nitrogen mustard, vincristine, and prednisone for the adjuvant treatment of medulloblastoma	Equivocal/Weak For	Moderate
Rasburicase (Internal Review)	7/10/15	For the treatment of hyperuricemia in patients with leukemia, lymphoma, or solid tumors who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid	Equivocal/Weak For	Very Low
Regorafenib (Internal Review)	2/1/17	For the treatment of hepatocellular cancer in patients who have progressed on sorafenib therapy	Equivocal/Weak For	Moderate
Rituximab (External Request - Genentech Inc, a member of the Roche Group)	12/14/11	For the use of rituximab in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia in elderly patients	Equivocal/Weak For	Very Low
Rituximab (External Request - Genentech Inc, a member of the Roche Group)	5/26/16	For the use of rituximab in combination with lenalidomide for the treatment of mantle cell lymphoma	Equivocal/Weak For	Low
Rituximab (External Request - Genentech Inc, a member of the Roche Group)	1/19/12	For the use of rituximab as maintenance therapy in patients with mantle-cell lymphoma	Equivocal/Weak For	Moderate

Rituximab (External Request - Genentech Inc, a member of the Roche Group)	1/27/12	For the use of rituximab in combination with lenalidomide for the first-line treatment of indolent non-Hodgkin's lymphoma	Equivocal/Weak For	Very Low
Rituximab (Internal Review)	12/14/11	For the use of rituximab in combination with fludarabine for the first-line treatment of chronic lymphocytic leukemia	Equivocal/Weak For	Low
Rituximab (Internal Review)	12/15/11	For the use of rituximab in combination with hyper-CVAD chemotherapy for the treatment of CD20+ acute lymphocytic leukemia	Strong For	Low
Rituximab (Internal Review)	12/15/11	For the use of rituximab in combination with Hyper-CVAD chemotherapy for the treatment of Burkitt's lymphoma	Strong For	Very Low
Rituximab (Internal Review)	1/19/12	For the use of rituximab in combination with CHOP chemotherapy for the treatment of previously untreated advanced mantle cell lymphoma	Strong For	Moderate
Rituximab (Internal Review)	1/19/12	For the use of rituximab in combination with hyper-CVAD chemotherapy for the treatment of previously untreated advanced mantle cell lymphoma	Strong For	Low
Rituximab (Internal Review)	1/27/12	For the use of rituximab in combination with CHOP chemotherapy for the treatment of follicular non-Hodgkin's lymphoma	Strong For	Moderate
Rituximab (Internal Review)	9/21/15	For the use of rituximab in combination with fludarabine and mitoxantrone for the treatment of previously untreated follicular non-Hodgkin's lymphoma	Weak For	Low
Rituximab (Internal Review)	8/24/12	For the use of rituximab for the treatment of steroid-refractory chronic graft-versus-host disease	Equivocal/Weak For	Low
Rituximab (Internal Review)	8/18/16	For the use of dexamethasone, rituximab, and cyclophosphamide for the treatment of newly diagnosed Waldenstrom macroglobulinemia	Strong For	Low
Rucaparib (Internal Review)	11/20/17	For the use of rucaparib for the maintenance treatment of recurrent high-grade ovarian, fallopian tube, or primary peritoneal cancer after response to platinum-based	Weak For	Moderate
Sorafenib (Internal Review)	10/14/11	Against the use of sorafenib for the single-agent treatment of advanced malignant melanoma	Equivocal/Weak Against	Low
Sorafenib (Internal Review)	10/14/11	For the use of sorafenib in combination with dacarbazine or temozolomide for the treatment of advanced malignant melanoma	Equivocal/Weak For	Moderate
Sorafenib (Internal Review)	10/14/11	Against the use of sorafenib in combination with carboplatin and paclitaxel for the treatment of advanced malignant melanoma	Strong Against	High
Streptozocin (Internal Review)	10/19/11	For the use of streptozocin in combination with 5-fluorouracil for the treatment of advanced carcinoid tumors	Equivocal/Weak For	Moderate
Streptozocin (Internal Review)	10/19/11	Against the use of streptozocin in combination with chemotherapy for the treatment of advanced colorectal cancer	Strong Against	Moderate
Talimogene laherparepvec (External Request - Amgen)	4/13/18	For the treatment of unresectable advanced melanoma in patients eligible for local treatment of cutaneous, subcutaneous, and nodal lesions, in combination with ipilimumab	Weak Against	Low
Tamoxifen (Internal Review)	10/12/11	For the use of tamoxifen for the treatment of desmoid tumor or fibromatosis	Equivocal/Weak For	Low
Tamoxifen (Internal Review)	10/14/11	Against the use of tamoxifen in combination with other agents for the treatment of metastatic malignant melanoma	Equivocal/Weak Against	Moderate
Tamoxifen (Internal Review)	10/18/11	For the use of tamoxifen for the treatment of malignant glioma	Equivocal/Weak For	Moderate
Tamoxifen (Internal Review)	10/20/11	For the use of tamoxifen for the treatment of relapsed or refractory ovarian cancer	Equivocal/Weak For	Low

Temozolomide (Internal Review)	10/14/11	For the use of temozolomide for the first-line treatment of metastatic melanoma	Strong For	High
Temozolomide (Internal Review)	10/18/11	Against the use of temozolomide for the treatment of newly diagnosed diffuse intrinsic brainstem glioma in pediatric patients	Equivocal/Weak Against	Low
Temozolomide (Internal Review)	10/18/11	For the use of temozolomide for the treatment of high-grade glioma in pediatric patients	Equivocal/Weak For	Low
Temozolomide (Internal Review)	10/20/11	For the use of temozolomide for the treatment of recurrent or relapsed glioblastoma multiforme	Strong For	Moderate
Temsirolimus (Internal Review)	10/5/11	For the use of temsirolimus for the treatment of heavily pretreated, relapsed or refractory mantle cell lymphoma	Strong For	High
Temsirolimus (Internal Review)	8/24/12	Against the use of temsirolimus for the treatment of recurrent glioblastoma multiforme	Equivocal/Weak Against	Low
Temsirolimus (Internal Review)	8/24/12	Against the use of temsirolimus for the treatment of relapsed or refractory neuroblastoma in pediatric patients	Equivocal/Weak Against	Very Low
Temsirolimus (Internal Review)	8/24/12	Against the use of temsirolimus for the treatment of relapsed or refractory rhabdomyosarcoma	Equivocal/Weak Against	Very Low
Teniposide (Internal Review)	10/3/11	For the use of teniposide as first-line therapy for advanced follicular non-Hodgkin's lymphoma, in combination with cyclophosphamide, doxorubicin, prednisolone or prednisone, and interferon alfa-2b	Equivocal/Weak For	High
Teniposide (Internal Review)	10/3/11	For the use of teniposide as first-line therapy for intermediate- or high-grade non-Hodgkin's lymphoma, in combination with cyclophosphamide, doxorubicin, prednisone, bleomycin, and vincristine	Equivocal/Weak For	Moderate
Teniposide (Internal Review)	10/10/11	For the use of teniposide for the first-line treatment of inoperable, locally advanced or metastatic non-small cell lung cancer, in combination with cisplatin	Equivocal/Weak For	High
Teniposide (Internal Review)	10/18/11	For the use of teniposide for the treatment of previously untreated advanced neuroblastoma, in combination with cisplatin or cisplatin, cyclophosphamide, and doxorubicin	Equivocal/Weak For	Low
Teniposide (Internal Review)	10/18/11	Against the use of teniposide for the treatment of advanced bladder cancer	Equivocal/Weak Against	Low
Teniposide (Internal Review)	10/23/11	For the use of teniposide for the treatment of previously untreated small cell lung cancer	Equivocal/Weak For	Moderate
Thalidomide (Internal Review)	5/1/12	For the use of thalidomide for the treatment of AIDS-related Kaposi's sarcoma	Equivocal/Weak For	Very Low
Thalidomide (Internal Review)	8/22/12	Against the use of thalidomide for the treatment of primary malignant glioma, including astrocytoma	Equivocal/Weak Against	Low
Thalidomide (Internal Review)	8/22/12	For the use of thalidomide in combination with chemotherapy or radiation for the treatment of primary malignant glioma, including astrocytoma	Equivocal/Weak For	Very Low
Thalidomide (Internal Review)	8/24/12	For the use of thalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma	Equivocal/Weak For	Very Low
Thalidomide (Internal Review)	8/24/12	For the use of thalidomide as part of the Total Therapy 2 regimen for the treatment of newly diagnosed multiple myeloma	Strong For	Moderate
Thalidomide (Internal Review)	8/30/12	For the use of thalidomide in combination with melphalan and prednisone for the treatment of newly diagnosed multiple myeloma in elderly or transplant ineligible patients	Strong For	Moderate
Thalidomide (Internal Review)	12/4/12	For the use of thalidomide for the treatment of transfusion dependent myelodysplastic syndrome	Equivocal/Weak For	Very Low
Thalidomide (Internal Review)	12/7/12	Against the use of thalidomide in combination with steroids and either cyclosporine or tacrolimus for the treatment of chronic graft-versus-host disease	Equivocal/Weak Against	Low
Thiotepa (Internal Review)	10/13/11	For the use of thiotepa for the treatment of carcinomatous meningitis	Strong For	Low

Thiotepa (Internal Review)	10/13/11	Against the use of thiotepa for the treatment of recurrent soft tissue sarcoma	Equivocal/Weak Against	Very Low
Thiotepa (Internal Review)	10/14/11	For the use of thiotepa in combination with busulfan and cyclophosphamide for stem cell transplant preparation prior to autologous or allogeneic transplant in patients with hematologic malignancy	Equivocal/Weak For	Low
Topotecan (Internal Review)	10/10/11	For the use of topotecan in combination with gemcitabine for the second-line treatment of non-small cell lung cancer	Equivocal/Weak For	Low
Topotecan (Internal Review)	10/10/11	For the use of topotecan in combination with gemcitabine for the treatment of previously untreated advanced non-small cell lung cancer	Equivocal/Weak For	Low
Topotecan (Internal Review)	10/21/11	Against the use of topotecan in combination with cyclophosphamide and vincristine alternating with VAC for the treatment of metastatic rhabdomyosarcoma	Equivocal/Weak Against	High
Topotecan (Internal Review)	10/23/11	Against the use of topotecan in combination with paclitaxel for previously untreated extensive-stage small cell lung cancer	Equivocal/Weak Against	Low
Topotecan (Internal Review)	10/23/11	Against the use of topotecan for chemotherapy-naive extensive-stage small cell lung cancer sequentially after cisplatin and etoposide	Equivocal/Weak Against	High
Tositumomab (Internal Review)	12/1/14	For the use of tositumomab for the treatment of previously untreated follicular non-Hodgkin's lymphoma (NHL) after induction with CHOP chemotherapy	Equivocal/Weak For	Moderate
Tositumomab (Internal Review)	10/14/11	For the use of tositumomab for use in stem-cell preparation prior to autologous transplant for relapsed or refractory non-Hodgkin's lymphoma	Equivocal/Weak For	Low
Trastuzumab (External Request - Genetech)	10/3/11	For the use of trastuzumab in combination with anastrozole for the treatment of postmenopausal patients with HER2-positive, hormone receptor-positive metastatic breast cancer	Strong For	High
Trastuzumab (Internal Review)	10/3/11	For the use of trastuzumab in combination with paclitaxel and carboplatin for the front-line treatment of HER2-overexpressing metastatic breast cancer	Strong For	Moderate
Trastuzumab (Internal Review)	10/3/11	For the use of docetaxel in combination with trastuzumab for the treatment of HER2-positive metastatic breast cancer	Strong For	Moderate
Trastuzumab (Internal Review)	10/3/11	For the use of trastuzumab for the neoadjuvant treatment of HER2-positive locally advanced breast cancer sequential to and in combination with doxorubicin, paclitaxel, and CMF chemotherapy	Strong For	High
Trastuzumab (Internal Review)	10/3/11	For the use of trastuzumab in combination with lapatinib for the treatment of HER2-positive, trastuzumab-refractory metastatic breast cancer	Strong For	Moderate
Trastuzumab (Internal Review)	10/3/11	For the use of trastuzumab in combination with vinorelbine for the treatment of HER2-positive metastatic breast cancer	Strong For	Moderate
Trastuzumab (Internal Review)	10/3/11	For the use of trastuzumab in combination with cisplatin and 5-fluorouracil or capecitabine for the treatment of HER2-positive, inoperable, locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or gastroesophageal junction	Strong For	High
Trastuzumab (Internal Review)	8/20/12	For the use of trastuzumab for the neoadjuvant treatment of HER2-positive breast cancer sequential to and in combination with paclitaxel and FEC chemotherapy	Strong For	Moderate
Tretinoin (Internal Review)	10/10/11	Against the use of tretinoin for the treatment of AIDS-related Kaposi's sarcoma	Equivocal/Weak Against	Low
Tretinoin (Internal Review)	10/12/11	For the use of tretinoin as maintenance therapy for acute promyelocytic leukemia following induction and consolidation therapy	Equivocal/Weak For	Moderate

Tretinoin (Internal Review)	12/18/13	For the use of tretinoin in combination with arsenic trioxide for remission induction and consolidation treatment in patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukemia (APL)	Equivocal/Weak For	Low
Tretinoin (Internal Review)	12/20/13	For the use of tretinoin in combination with idarubicin for remission induction treatment in patients with newly diagnosed acute promyelocytic leukemia (APL)	Strong For	Low
Tretinoin (Internal Review)	12/20/13	For the use of tretinoin in combination with idarubicin-containing chemotherapy for consolidation treatment following tretinoin and idarubicin induction therapy in patients with newly diagnosed acute promyelocytic leukemia (APL)	Strong For	Low
Triptorelin (Internal Review)	10/3/11	For the use of triptorelin for the treatment of premenopausal women with hormone-sensitive advanced breast cancer	Equivocal/Weak For	Very Low
Vemurafenib (External Request)	3/13/18	For the use of vemurafenib for the treatment of BRAF mutation-positive, RAS wild-type, metastatic colorectal cancer, in combination with irinotecan and cetuximab	Equivocal/Weak For	Very Low
Vemurafenib (External Request)	5/2/18	Against the use of vemurafenib for the adjuvant treatment of completely resected stage IIC to IIIC melanoma in patients with the BRAF V600 mutation	Strong Against	Low
Venetoclax (Internal Review)	4/20/18	For the use of venetoclax for treatment of relapsed or refractory chronic lymphocytic leukemia, in combination with rituximab	Strong For	Moderate
Vinblastine (Internal Review)	10/10/11	For the use of vinblastine as adjuvant therapy in resected non-small cell lung cancer, in combination with cisplatin	Equivocal/Weak For	Moderate
Vinblastine (Internal Review)	10/10/11	For the use of vinblastine as first-line treatment of inoperable, stage II or III non-small cell lung cancer, in combination with cisplatin and radiotherapy	Strong For	High
Vinblastine (Internal Review)	10/12/11	Against the use of vinblastine for first-line chemotherapy in metastatic hormone-refractory prostate cancer, in combination with estramustine	Strong Against	High
Vinblastine (Internal Review)	10/14/11	For the use of vinblastine for the first-line treatment of metastatic malignant melanoma, in combination with cisplatin and dacarbazine	Equivocal/Weak For	Moderate
Vincristine (Internal Review)	9/14/12	For the use of vincristine, in combination with cisplatin, methotrexate and bleomycin, for the treatment of recurrent or metastatic squamous cell head and neck cancer	Equivocal/Weak For	Moderate
Vinorelbine (Internal Review)	10/3/11	For the use of vinorelbine for the treatment of metastatic breast cancer, in patients previously treated with anthracycline and/or taxane therapy	Strong For	High
Vinorelbine (Internal Review)	10/10/11	For the use of vinorelbine for the treatment of recurrent or metastatic squamous cell head and neck cancer	Equivocal/Weak For	Low
Vinorelbine (Internal Review)	10/10/11	For the use of vinorelbine in combination with cisplatin as adjuvant therapy in resected non-small cell lung cancer	Strong For	High
Vinorelbine (Internal Review)	10/12/11	For the use of vinorelbine in combination with other chemotherapy agents as salvage therapy in relapsed or refractory Hodgkin's disease	Equivocal/Weak For	Low
Vinorelbine (Internal Review)	10/12/11	For the use of vinorelbine in combination with methotrexate for the treatment of desmoid tumor or aggressive fibromatosis	Equivocal/Weak For	Very Low
Vinorelbine (Internal Review)	10/20/11	For the use of vinorelbine for the treatment of recurrent ovarian cancer	Equivocal/Weak For	Low
Zoledronic Acid (External Request - Novartis)	10/3/11	For the use of zoledronic acid for the adjuvant treatment of early breast cancer in women with postmenopausal reproductive hormone levels	Equivocal/Weak For	Moderate

NOTE: For information regarding editorial evaluation of off-label indications and recommendations, see Gold Standard/Elsevier Editorial Policy for Off-Label Data within Drug Information Products